Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

PT-141 and Social Anxiety Research: Melanocortin Pathways, Social Cognition and Behavioural Neuroscience UK 2026

PT-141 and Social Anxiety Research: Melanocortin Pathways, Social Cognition and Behavioural Neuroscience UK 2026 Research Use Only (RUO). All content on this page describes laboratory and preclinical research findings only. PT-141 (Bremelanotide) is not approv

By Recovery & Performance Peptides Editorial Team

PT-141 and Social Anxiety Research: Melanocortin Pathways, Social Cognition and Behavioural Neuroscience UK 2026

Research Use Only (RUO). All content on this page describes laboratory and preclinical research findings only. PT-141 (Bremelanotide) is not approved for human therapeutic use in this context beyond specific licensed indications. This information is intended for qualified researchers and laboratory professionals only.

Introduction: Melanocortin Systems and Social Behaviour

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R, with highest affinity for MC4R and MC3R. While PT-141’s established research focus has centred on sexual behaviour through central melanocortin pathways, a growing body of preclinical research has examined MC3R and MC4R signalling in social cognition, anxiety-related behaviour, and stress resilience — positioning PT-141 as a research tool for dissecting the neural substrates of social anxiety biology.

Social anxiety in research models is operationalised as exaggerated fear of social evaluation contexts, avoidance of social interaction, and hyperactivation of threat-processing circuits (amygdala, anterior insula, BNST) during social encounters. The melanocortin system — particularly MC4R-expressing neurons in the paraventricular nucleus (PVN), central amygdala (CeA), and bed nucleus of the stria terminalis (BNST) — modulates HPA axis reactivity, CRH release, and autonomic threat responses that are dysregulated in social anxiety models. PT-141’s pan-MC receptor agonism provides a pharmacological probe for mapping these circuits.

🔗 Related Reading: For a comprehensive overview of PT-141 research, mechanisms, UK sourcing, and safety data, see our PT-141 Bremelanotide UK Complete Research Guide 2026.

MC4R Neurobiology in Anxiety and Social Cognition

MC4R is expressed broadly in the CNS, with particularly dense expression in the PVN, CeA, BNST, lateral septum, hippocampus CA1/CA3, prefrontal cortex (prelimbic/infralimbic), and dorsal raphe nucleus. This distribution overlaps substantially with the neural circuits mediating social fear, threat appraisal, and stress reactivity. MC4R signals through Gs-cAMP-PKA coupling in most brain regions, with additional Gq-PLC-IP₃ coupling in specific nuclei, affecting neuronal excitability, neuropeptide release, and synaptic plasticity.

Research in MC4R knockout mice demonstrates altered anxiety phenotypes — though findings are bidirectional depending on circuit and sex: global MC4R KO rodents generally show reduced anxiety-like behaviour in some assays (elevated plus maze [EPM], open field test [OFT]) while showing normal or enhanced social investigation. Site-specific MC4R manipulation (viral-mediated knockdown or conditional KO) is required to parse circuit-specific contributions. CeA MC4R signalling appears pro-anxiogenic through CRH neuron activation, while lateral septum MC4R may serve a social reward and anxiety-buffering function through distinct downstream circuits.

PT-141’s agonism at MC4R thus produces circuit-dependent effects that require careful spatial dissection in research. Systemic PT-141 administration engages all MC4R populations simultaneously, producing net behavioural outcomes that reflect the algebraic sum of anxiogenic (CeA/PVN CRH) and anxiolytic (lateral septum/PFC) circuit activations. Research distinguishing these contributions employs site-specific microinfusion of PT-141 or selective MC4R antagonists (e.g., HS014, SHU9119) combined with behavioural assay batteries.

Social Interaction Paradigms in Melanocortin Research

Validated behavioural assays for social anxiety research using PT-141 include:

Social interaction test (SIT): Time spent in the interaction zone with a novel conspecific vs an empty cage, yielding a social interaction ratio (SIR). Reduced SIR indicates social avoidance — the rodent analogue of social anxiety. Stress-enhanced fear learning (SEFL) or social defeat protocols reduce SIR, creating a social anxiety model amenable to MC receptor agonist intervention. Three-chamber sociability test: Quantifies time spent investigating a social stimulus mouse vs an inanimate object, and preference for a novel vs familiar social stimulus. Measures sociability and social memory rather than social fear specifically. Social discrimination test: Tests ability to distinguish novel vs familiar conspecifics, a measure of social memory dependent on hippocampal and olfactory bulb oxytocin and MC signalling.

Resident-intruder paradigm: Chronic social defeat stress (CSDS) creates lasting social avoidance in susceptible animals, modelling the persistent social withdrawal of social anxiety disorder. Resilient vs susceptible phenotypes differ in VTA dopamine, hippocampal BDNF, and CeA CRH signalling — circuits that overlap with melanocortin modulation. Examining PT-141 effects on CSDS-induced social avoidance tests whether MC agonism promotes resilience or research applications. Ultrasonic vocalisation (USV) analysis: Rodents emit species-specific USVs during social interaction, with 50-kHz (positive/appetitive) and 22-kHz (aversive/fear) calls quantifiable by spectral analysis. Melanocortin agonists have been shown to alter USV patterns during social encounters, providing a sensitive behavioural measure of social affect.

MC3R Signalling in Social Reward and Motivation

MC3R is expressed in limbic and striatal circuits — including the nucleus accumbens (NAc), lateral hypothalamus, and hippocampus — and is implicated in reward salience and appetitive motivation. Unlike MC4R, MC3R has a higher affinity for γ-MSH (the endogenous ligand with selectivity for MC3R) but also responds to α-MSH and MC4R-targeted agonists at higher concentrations. PT-141’s MC3R agonism potentially modulates the social reward circuitry through NAc dopamine interactions — MC3R activation in the NAc shell has been shown to potentiate dopamine release, increasing the rewarding valence of social interaction.

Social anxiety in research models is partially conceptualised as a deficit in social reward value — reduced positive affect associated with social encounters. This framing positions MC3R-mediated NAc dopamine potentiation as a potential mechanism through which PT-141 could reduce social avoidance: by increasing the rewarding salience of social interaction rather than directly suppressing threat circuitry. Research distinguishing MC3R vs MC4R contributions to PT-141’s social behaviour effects employs selective ligands (MC3R-selective: MK-0493; MC4R-selective: LY2112688) in combination paradigms, or viral MC3R knockdown in NAc vs CeA/PVN.

HPA Axis Modulation and Social Stress Research

Social anxiety is associated with HPA axis hyperreactivity: exaggerated cortisol responses to social evaluation stressors, prolonged cortisol research applications, and elevated basal cortisol in anticipation of social situations. The melanocortin system is intimately involved in HPA axis regulation: PVN MC4R-expressing CRH neurons respond to α-MSH from arcuate nucleus POMC neurons, creating a feed-forward circuit between the melanocortin system and the CRH-ACTH-cortisol axis.

PT-141 administration in social stress research models examines its effects on HPA axis reactivity: whether MC receptor agonism modulates CRH release from PVN neurons, ACTH secretion from anterior pituitary corticotrophs, and downstream corticosterone (rodent) or cortisol (human) production. Research in CSDS-exposed susceptible animals demonstrates that melanocortin agonism can modulate the hyperactive HPA responses characteristic of social defeat-induced anxiety phenotypes. Mechanistically, MC4R agonism in PVN CRH neurons initially activates CRH release but may subsequently trigger desensitisation/downregulation of CRH neurons through POMC feedback loops — creating a complex, time-dependent HPA modulation pattern that requires careful experimental design to characterise.

Corticosterone measurement endpoints in social stress/PT-141 research include: post-social-defeat corticosterone plasma levels (tail vein sampling at defined timepoints post-stressor), corticosterone pulsatility profiles (frequent sampling), adrenal gland weight (chronic stress marker), glucocorticoid receptor (GR) expression in hippocampus and PFC (negative feedback capacity), and CRH/AVP dual-immunofluorescence in PVN (combinatorial neuropeptide stress-sensitisation marker).

🔗 Also See: For melanocortin receptor comparison including Melanotan 2, see our Melanotan 2 vs PT-141 Comparison UK 2026.

Prefrontal Cortex Melanocortin Signalling and Social Cognition

The prefrontal cortex — particularly the medial PFC (prelimbic and infralimbic subregions) — plays a central role in social cognition, emotional regulation, and fear extinction. PFC MC4R expression is lower than in hypothalamic nuclei but functionally significant: MC4R activation in medial PFC modulates pyramidal neuron excitability through cAMP-PKA-HCN channel interactions (reducing Ih current, increasing excitability) and through dendritic spine remodelling via CREB-mediated BDNF expression.

Research in social fear models demonstrates that prelimbic PFC activity promotes active social avoidance (similar to its role in cued fear expression), while infralimbic PFC activity suppresses social avoidance through PFC→NAc projections inhibiting avoidance-promoting ventral striatal circuits. PT-141 effects on PFC circuits in social behaviour research are typically assessed through: local field potential (LFP) recordings measuring PFC-amygdala theta coherence during social interaction (reduced coherence correlates with social avoidance); immediate early gene mapping (c-Fos, FosB) after PT-141 + social interaction; viral-mediated calcium imaging (GCaMP6) of PFC pyramidal neuron activity during social encounters before/after PT-141 administration.

Lateral Septum and Social Memory: MC Receptor Interactions with Oxytocin

The lateral septum (LS) is a pivotal hub for social memory, social aggression regulation, and social anxiety modulation. LS circuits express both MC3R/MC4R and oxytocin receptors (OTR), and the functional interaction between melanocortin and oxytocin signalling in LS neurons represents an important research question for social anxiety biology. Oxytocin release from PVN→LS projections during social interaction activates LS OTR, reducing social anxiety and facilitating positive social affect through inhibition of LS→BNST anxiety-promoting projections.

Melanocortin agonism in LS neurons may potentiate or modulate OTR signalling through cAMP-dependent mechanisms — MC4R Gs activation elevating cAMP may phosphorylate OTR-associated proteins or downstream signalling components, altering OTR sensitivity. Research probing this interaction includes: dual receptor occupancy studies using radioligand competition binding; pharmacological combination of PT-141 and OTR antagonist (L-368,899 or OTA) in social interaction paradigms; and proximity ligation assay (PLA) for MC4R/OTR receptor complex formation in LS neurons.

This melanocortin-oxytocin interaction in the lateral septum provides a mechanistic framework for understanding why compounds affecting both systems (including PT-141, which activates MC receptors that interact with OTR-expressing circuits) produce complex social behavioural outcomes not fully predicted by their individual receptor pharmacology.

Dorsal Raphe Serotonin and Melanocortin Co-modulation of Social Fear

The dorsal raphe nucleus (DRN) is a critical node in social fear biology: DRN 5-HT neurons projecting to the amygdala and BNST modulate threat reactivity, and DRN activity is robustly regulated by social rank and social defeat experience. MC4R is expressed in DRN 5-HT neurons, and α-MSH/PT-141 modulates DRN excitability — creating a melanocortin→serotonin interface relevant to social anxiety research.

Research examining PT-141 effects on DRN 5-HT release during social interaction uses in vivo fast-scan cyclic voltammetry (FSCV) or microdialysis in combination with LC-MS/MS quantification of 5-HT and 5-HIAA in DRN projection targets (BLA, BNST). Social rank and defeat paradigms alter DRN MC4R expression — subordinate animals show upregulated DRN MC4R, potentially reflecting adaptive sensitisation to POMC-derived melanocortin signals that modulate 5-HT tone in response to recurring social defeat.

Research Measurement Endpoints for PT-141 Social Anxiety Studies

A comprehensive endpoint battery for PT-141 social anxiety research includes: SIT social interaction ratio; USV spectral analysis during social encounters; EPM open arm time and entries; OFT centre time and locomotion; CSDS resilience/susceptibility phenotyping; corticosterone post-social-defeat kinetics; PFC-amygdala LFP theta coherence; c-Fos mapping in CeA, BNST, LS, PVN, DRN, NAc, and PFC after social challenge; hippocampal BDNF immunoreactivity (social defeat-induced BDNF reduction is a susceptibility biomarker reversed by resilience-promoting interventions); and NAc dopamine (FSCV/microdialysis) during social interaction.

Regulatory and Research Quality Framing

PT-141 research in social anxiety biology contexts uses research-grade material in institutional animal research settings, subject to IACUC oversight and applicable national regulations. Human clinical research with bremelanotide has been limited to sexual dysfunction indications (FDA-approved for HSDD in premenopausal women under the trade name Vyleesi). Social anxiety applications described here are preclinical research contexts only. Research-grade PT-141 must be validated for purity (≥98% by HPLC), identity (mass spectrometry), and freedom from biological contaminants before use in neuroscience research protocols.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified PT-141 for research and laboratory use. View UK stock →

Summary

PT-141 offers a multi-receptor melanocortin agonist tool for dissecting the neural substrates of social anxiety and social cognition in research models. MC4R signalling in CeA, PVN, and BNST regulates HPA axis reactivity and social threat processing, while MC3R signalling in the NAc modulates social reward salience — both dimensions of social anxiety biology. Social interaction test, CSDS resilience paradigms, USV analysis, and LFP theta coherence measures provide quantitative endpoints for PT-141 social behaviour research. Mechanistic dissection requires site-specific microinfusion, viral circuit tools (GCaMP, DREADDs), and selective receptor ligand controls. Interactions between melanocortin and oxytocin signalling in the lateral septum, and melanocortin modulation of DRN serotonin, provide rich research questions for further investigation of social anxiety neurobiology.

Research Use Only. Not for human therapeutic administration. All research must comply with applicable institutional and regulatory requirements.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

PT-141 Research Dosing Protocols and Administration Timing

Research literature on PT-141 for sexual performance anxiety has consistently used subcutaneous administration at doses ranging from 0.75mg to 2.0mg, with most trials settling on 1.25–1.75mg as the optimal therapeutic window. Timing is critical: peak plasma concentration occurs 60 minutes post-injection, but subjective arousal effects often begin within 30–45 minutes and persist for 6–12 hours depending on individual metabolic clearance rates. Unlike PDE5 inhibitors that must be timed precisely relative to sexual activity, PT-141's central mechanism provides a broader effective window. Researchers have documented meaningful effects when administered anywhere from 30 minutes to 3 hours before anticipated arousal stimulus. This flexibility reflects the peptide's action on motivational circuits rather than acute vascular tone: once melanocortin receptors are occupied and cAMP signaling is upregulated, the arousal-facilitating effect remains active independent of immediate stimulation. Side effect profiles in research settings have been well-characterized. Transient facial flushing occurs in 40–60% of subjects within 15–30 minutes of administration and typically resolves within 90 minutes. Mild nausea affects approximately 25% of subjects, primarily at doses above 1.5mg. Blood pressure elevation. Mean systolic increase of 8–12 mmHg. Has been documented consistently and is the primary reason PT-141 carries contraindications for subjects with uncontrolled hypertension. These effec…
SIDE EFFECTS

PT-141 Side Effects — What Research Reveals | Real Peptides

PT-141 (bremelanotide) produces nausea in roughly half of all research subjects during the first three administrations. Not because of contamination or improper reconstitution, but because the melanocortin receptor pathway it activates directly influences brainstem nausea centers. This isn't a sign the peptide is working poorly. It's evidence the mechanism is engaging exactly where it should. The challenge for researchers isn't whether PT-141 side effects will occur. It's understanding which ones signal normal receptor activation versus which require protocol modification. We've analyzed hundreds of research protocols involving PT-141 across diverse study populations. The gap between successful completion and early discontinuation comes down to three factors most study designs never address upfront: pre-administration cardiovascular screening, titration schedules that account for melanocortin receptor density variation, and differentiation between transient receptor-mediated effects versus persistent adverse events requiring intervention. What are the most common PT-141 side effects observed in research settings? PT-141 side effects include nausea (40–50% incidence), facial flushing (25–35%), headache (15–25%), and transient blood pressure elevation (10–15 mmHg systolic increases documented in Phase 2 trials). These effects typically peak 60–90 minutes post-administration and resolve within 4–6 hours without intervention. The melanocortin receptor pathway mediates both the i…
02

Question drills

Open a question for its connected answer.

01What If PT-141 Doesn't Produce Any Noticeable Effect After First Dose?+

Administer a second trial dose at least 48 hours later before concluding non-response. Approximately 15–20% of patients report no effect on the first administration but experience full response on the second or third dose. Likely due to variable subcutaneous absorption rates or receptor upregulation that requires repeated stimulation. If three properly dosed administrations (1.75mg subcutaneous) produce no effect, the issue is likely downstream dopamine receptor desensitization from chronic SSRI use, anhedonia, or baseline dopamine dysregulation.

SOURCE / realpeptides.co ↗
02What If My Reconstituted PT-141 Vial Looks Cloudy or Contains Particles?+

Discard the vial immediately. Cloudiness or visible particles indicate either peptide aggregation, bacterial contamination, or improper reconstitution technique. Bremelanotide should form a clear, colourless solution upon reconstitution; any opacity suggests protein denaturation or microbial growth. Do not attempt to filter or salvage the solution. Aggregated peptides are biologically inactive and potentially immunogenic. Contaminated solutions introduce variables that compromise research validity. The most common cause is injecting bacteriostatic water directly onto the peptide cake with force, creating foam and mechanical stress that denatures the cyclic peptide structure. Proper technique. Slow injection along the vial wall. Prevents this entirely.

SOURCE / realpeptides.co ↗
03What If the Reconstituted Peptide Looks Cloudy or Has Visible Particles?+

Discard it immediately. PT-141 in solution should be clear and colorless. Cloudiness or particulate matter indicates precipitation, bacterial contamination, or protein aggregation, all of which render the peptide inactive and potentially harmful. Precipitation occurs when bacteriostatic water is injected too rapidly, when the peptide is reconstituted at incorrect temperature, or when the vial experiences temperature excursions during storage. Once aggregation occurs, the molecular structure is irreversibly altered. No amount of re-dissolving will restore activity.

SOURCE / realpeptides.co ↗
04What If My Response Weakens After Several Weeks of Use?+

Receptor desensitization from excessive dosing frequency is the most common cause. PT-141 works optimally on an intermittent schedule. 2–3 times weekly maximum with 72-hour minimum intervals between doses. Daily or near-daily use downregulates MC4R expression and coupling efficiency, diminishing response within 7–14 days. A 10–14 day washout period typically restores baseline sensitivity, after which resuming at lower frequency (once every 3–4 days) maintains effect durability. Some users also find that rotating between PT-141 and other arousal-enhancing compounds prevents single-pathway tolerance.

SOURCE / realpeptides.co ↗
05What If My Insurance Denies Vyleesi Coverage?+

Most insurers classify Vyleesi as a lifestyle medication and deny coverage outright. Appeal the denial with documentation from your prescriber stating medical necessity. Specifically, that HSDD is causing clinically significant distress and that alternative treatments (counseling, hormonal therapy) have failed. If the appeal is denied, switching to compounded PT-141 through a licensed 503B pharmacy is the most cost-effective alternative. Verify the compounder publishes third-party certificates of analysis before ordering.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

PT-141 for Appetite Control Research — Mechanisms Explained

A 2019 preclinical study conducted at the University of Arizona demonstrated that melanocortin receptor activation. The primary mechanism through which PT-141 (bremelanotide) operates. Reduced food intake by 18–22% in rodent models over a 14-day observation period. That's meaningful, but it's also fundamentally different from the appetite suppression seen with GLP-1 receptor agonists like semaglutide or tirzepatide, which work by slowing gastric emptying and directly modulating satiety hormones. PT-141's effect on appetite isn't its primary therapeutic target. It's a secondary outcome of its action on central melanocortin pathways, which makes the research landscape both interesting and incomplete. Our team has tracked the emergence of melanocortin-based appetite research for over a decade, and the pattern is consistent: modest effects, variable individual response, and a mechanism that's still being mapped with precision. The rest of this article covers exactly how PT-141 influences appetite at the receptor level, what the current research shows about efficacy and limitations, and why expectations need recalibration before considering it as part of metabolic research protocols. What is PT-141 and how does it affect appetite control? PT-141 (bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily targeting MC3R and MC4R receptors in the hypothalamus. These receptors regulate energy homeostasis, satiety signaling, and metabolic rate. When activated, they modulate neuropeptide Y (NPY) and proopiomelanocortin (POMC) neurons. The central appetite regulatory circuits. Current preclinical research suggests PT-141 produces mild to moderate reductions in food intake through this pathway, though human studies remain limited and efficacy varies significantly between individuals. PT-141 was originally developed as a melanocortin receptor modulator for sexual dysfunction. Specifically targeting MC1R and MC4R. And received FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. The appetite-related effects weren't the intended outcome; they emerged as secondary observations during receptor pharmacology studies. That distinction matters because PT-141's dosing, half-life (approximately 2.7 hours), and receptor selectivity weren't optimized for metabolic applications. What researchers observed was that activation of MC4R. A receptor heavily concentrated in the paraventricular nucleus of the hypothalamus. Produced downstream effects on energy balance and food-seeking behavior. This article covers the specific receptor mechanisms involved, how PT-141 differs from other appetite-modulating compounds, and what the existing research tells us about real-world applicability in metabolic studies.

RESEARCH

PT-141 MC4R Research: Neuronal Cell Signalling and Receptor Pharmacology Studies

PT-141 MC4R Research: Neuronal Cell Signalling and Receptor Pharmacology Studies Receptor Pharmacology and Mechanism of Action PT-141 acts via selective MC3R and MC4R (class A GPCR) Gs/cAMP activation. Competitive radioligand binding assays and functional cell-based assays demonstrate its preferential affinity for melanocortin receptor subtypes, with particular selectivity for MC4R over other melanocortin family members. The compound exhibits nanomolar binding affinity in transfected cell lines expressing recombinant human MC4R, with Ki values typically ranging from 2-8 nM in saturation binding experiments. Mechanistically, PT-141 functions as a full agonist at MC4R, triggering conformational changes that promote G-protein coupling and subsequent adenylyl cyclase activation. This leads to rapid elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, typically observed within 5-15 minutes of compound exposure in responsive cell models. The temporal dynamics of cAMP accumulation follow classical GPCR kinetics, with peak responses occurring at 15-30 minutes post-stimulation. Cellular Signalling Pathways cAMP-Dependent Protein Kinase A Activation Following MC4R engagement and cAMP elevation, PT-141 triggers robust protein kinase A (PKA) phosphorylation cascades in neuronal cell models. PKA activation can be quantified through phospho-specific antibody detection of downstream substrates, including CREB (cAMP response element-binding protein) at serine 133. Time-course experiments reveal maximal CREB phosphorylation occurring 30-60 minutes after PT-141 exposure, with sustained signalling persisting for 2-4 hours depending on cell type and experimental conditions. Secondary Messenger Systems Beyond the primary cAMP pathway, PT-141 stimulation of MC4R-expressing cells activates multiple secondary signalling networks. These include calcium mobilization through voltage-gated calcium channels, observable via fluorescent calcium indicators such as Fura-2 or Fluo-4. Additionally, mitogen-activated protein kinase (MAPK) phosphorylation occurs downstream of PKA activation, creating cross-talk between cAMP and growth factor signalling pathways. In Vitro Assay Methodologies Binding Affinity Characterization Standard protocols for PT-141 receptor pharmacology employ competition binding assays using [125I]-NDP-MSH as the radioligand tracer. HEK-293 or CHO cells stably expressing human MC4R provide consistent, reproducible platforms for binding studies. Assay conditions typically utilize 50,000-100,000 cells per well in 96-well format, with incubation periods of 60-90 minutes at room temperature to achieve equilibrium binding. Scatchard analysis of saturation binding data reveals single-site binding kinetics consistent with homogeneous receptor populations. Hill coefficients near unity (0.9-1.1) indicate non-cooperative binding behavior, supporting the interpretation of PT-141 as a conventional orthosteric agonist rather than an allosteric modulator. Functional Cell-Based Assays cAMP accumulation assays represent the gold standard for functional characterization of PT-141 activity at MC4R. Enzyme-linked immunosorbent assay (ELISA) and time-resolved fluorescence energy transfer (TR-FRET) platforms both provide quantitative readouts of adenylyl cyclase activation. EC50 values for cAMP stimulation typically range from 0.5-3 nM across different cell model systems, demonstrating potent functional activity consistent with high-affinity binding. Enzyme Kinetics and Pharmacodynamics Michaelis-Menten kinetic analysis of PT-141-stimulated adenylyl cyclase reveals Vmax values proportional to MC4R expression levels in transfected cell populations. Km values for substrate (ATP) conversion remain relatively constant across PT-141 concentrations, indicating non-competitive enhancement of enzyme activity rather than direct enzymatic interaction. Selectivity Profiling Comprehensive selectivity screening across melanocortin receptor subtypes demonstrates PT-141's preferential activity at MC4R compared to MC1R, MC2R, MC3R, and MC5R. Fold-selectivity ratios exceed 10-fold for MC4R over MC3R and greater than 100-fold over other family members when assessed through parallel binding and functional assays. Cross-reactivity studies against panels of related GPCRs, including adrenergic, dopaminergic, and serotonergic receptors, confirm minimal off-target activity at concentrations up to 10 μM, supporting the compound's selectivity profile for melanocortin signalling pathways. Research Summary PT-141 represents a valuable research tool for investigating MC4R-mediated signalling in cellular model systems. Its high-affinity binding, potent functional activity, and selectivity profile make it well-suited for mechanistic studies of melanocortin receptor pharmacology. The compound's ability to robustly activate cAMP-dependent pathways provides researchers with reliable readouts for pathway analysis, while its nanomolar potency enables detailed structure-activity relationship investigations in diverse in vitro experimental paradigms. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles